HitGen Inc
SSE:688222
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.47
17.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
HitGen Inc
HitGen Inc
Operating Income
HitGen Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
HitGen Inc
SSE:688222
|
Operating Income
¥31.3m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Operating Income
¥10.6B
|
CAGR 3-Years
37%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Operating Income
¥1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Operating Income
¥3.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Operating Income
¥1.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
27%
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Operating Income
¥410.8m
|
CAGR 3-Years
127%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
HitGen Inc
Glance View
HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. The company is headquartered in Chengdu, Sichuan and currently employs 508 full-time employees. The company went IPO on 2020-04-16. The firm focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The firm mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The firm conducts its businesses within the domestic market and to overseas markets.
See Also
What is HitGen Inc's Operating Income?
Operating Income
31.3m
CNY
Based on the financial report for Dec 31, 2023, HitGen Inc's Operating Income amounts to 31.3m CNY.
What is HitGen Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-8%
The average annual Operating Income growth rates for HitGen Inc have been -21% over the past three years , -8% over the past five years .
You don't have any saved screeners yet
